Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy...Wikipedia
Manufacturer's Website: Provenge Average retail cost: $31,00000/infusion